España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Pharvaris
PHVS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$19.50
0.67
3.56%
At close: -
$19.50
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Pharvaris (PHVS) Forecast
News
Earnings
Pharvaris (PHVS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Pharvaris (NASDAQ:PHVS) Stock
Pharvaris Stock (NASDAQ: PHVS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 13, 2024
Pharvaris Q3 EPS $(0.85) Misses $(0.67) Estim...
Benzinga Newsdesk
Thursday, October 24, 2024
Pharvaris Presents Clinical And Non-Clinical ...
Benzinga Newsdesk
Wednesday, October 16, 2024
Pharvaris To Present New Data On Hereditary A...
Benzinga Newsdesk
Thursday, October 03, 2024
Pharvaris Announced The Acceptance Of Six Abs...
Benzinga Newsdesk
Thursday, September 19, 2024
Jones Trading Initiates Coverage On Pharvaris...
Benzinga Newsdesk
Friday, September 06, 2024
Oppenheimer Maintains Outperform on Pharvaris...
Benzinga Newsdesk
Thursday, September 05, 2024
Pharvaris Highlights Oral Treatment For Hered...
Benzinga Newsdesk
Wednesday, July 03, 2024
Oppenheimer Maintains Outperform on Pharvaris...
Benzinga Newsdesk
Thursday, May 09, 2024
Wedbush Maintains Outperform on Pharvaris, Lo...
Benzinga Newsdesk
Wednesday, May 08, 2024
Pharvaris Q1 2024 Adj EPS €(0.52) Beats €(0.5...
Benzinga Newsdesk
Monday, April 22, 2024
Morgan Stanley Maintains Overweight on Pharva...
Benzinga Newsdesk
Monday, April 15, 2024
Morgan Stanley Maintains Overweight on Pharva...
Benzinga Newsdesk
Pharvaris shares are trading lower after the ...
Benzinga Newsdesk
Friday, April 12, 2024
Pharvaris NV Files For Mixed Shelf Offering; ...
Benzinga Newsdesk
Thursday, April 11, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Wedbush Reiterates Outperform on Pharvaris, M...
Benzinga Newsdesk
Wednesday, April 10, 2024
Pharvaris Q4 EPS $(0.80) Misses $(0.58) Estim...
Benzinga Newsdesk
Pharvaris N.V. Q4 2023 EPS €(0.74) Vs €(1.16)...
Benzinga Newsdesk
Pharvaris Appoints David Nassif As CFO
Benzinga Newsdesk
Tuesday, March 19, 2024
Wedbush Reiterates Outperform on Pharvaris, M...
Benzinga Newsdesk
Monday, March 18, 2024
Pharvaris Announces Phase 3 Clinical Study De...
Benzinga Newsdesk
Wednesday, March 06, 2024
Pharvaris Files For Resale Of Up To 5.55M Or...
Benzinga Newsdesk
Thursday, February 22, 2024
Pharvaris Stated That Positive Results From C...
Benzinga Newsdesk
Wednesday, February 14, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Tuesday, January 23, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Monday, January 22, 2024
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
Vandana Singh
Pharvaris shares are trading higher after the...
Benzinga Newsdesk
The FDA Has Lifted The Clinical Hold On Pharv...
Benzinga Newsdesk
Friday, January 05, 2024
Pharvaris Provides Business Update, Outlines ...
Benzinga Newsdesk
Thursday, December 07, 2023
B of A Securities Maintains Underperform on P...
Benzinga Newsdesk
Analyst Expectations for Pharvaris's Future
Benzinga Insights
Morgan Stanley Maintains Overweight on Pharva...
Benzinga Newsdesk
Wednesday, December 06, 2023
Gold Moves Higher; Campbell Soup Earnings Top Expectations
Lisa Levin
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks
Vandana Singh
Crude Oil Down 4%; Pharvaris Shares Spike Higher
Lisa Levin
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
Lisa Levin
US Stocks Higher; Private Payrolls Rise By 103,000 In November
Lisa Levin
Pharvaris shares are trading higher after the...
Benzinga Newsdesk
Pharvaris Announces Pricing of $300 Million U...
Benzinga Newsdesk
Pharvaris Announces Top-line Phase 2 Data fro...
Benzinga Newsdesk
Tuesday, November 14, 2023
Morgan Stanley Maintains Overweight on Pharva...
Benzinga Newsdesk
Thursday, November 09, 2023
Pharvaris Presents Deucrictibant Clinical Dat...
Benzinga Newsdesk
Friday, November 03, 2023
Wedbush Maintains Outperform on Pharvaris, Lo...
Benzinga Newsdesk
Monday, September 25, 2023
Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside
Vandana Singh
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Benzinga Insights
Wedbush Initiates Coverage On Pharvaris with ...
Benzinga Newsdesk
Monday, September 11, 2023
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday
Lisa Levin
Friday, August 18, 2023
Farfetch, Faraday Future Intelligent Electric, VinFast And Other Stocks Moving Lower On Friday
Lisa Levin
Tuesday, August 15, 2023
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
Show More